Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe.

Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Ørnbjerg, Lykke Midtbøll; Zavada, Jakub; Glintborg, Bente; MacDonald, Alan; Laas, Karin; Nordström, Dan; Gudbjornsson, Bjorn; Iannone, Florenzo; Hellmand, Pasoon; Kvien, Tore Kristian; Rodrigues, Ana Maria; Codreanu, Catalin; Rotar, Ziga; Castrejón Fernández, Isabel; Wallman, Johan Karlsson; ... (2023). Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe. The Lancet regional health. Europe, 33(100706), p. 100706. Elsevier 10.1016/j.lanepe.2023.100706

Preview

Text 1-s2.0-S2666776223001254-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview

This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021-April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.

Interest & Impact

Downloads

2 since deposited on 21 Aug 2023
2 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item